<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00811330</url>
  </required_header>
  <id_info>
    <org_study_id>3963</org_study_id>
    <nct_id>NCT00811330</nct_id>
  </id_info>
  <brief_title>Effects of High Dose Atorvastatin in Patients With Surgical Aortic Stenosis</brief_title>
  <official_title>Interest of Statin in Surgical Aortic Stenosis: From Myocardial Preconditioning to Ventricular Reverse Remodeling.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to see if statin therapy will optimize myocardial response to
      cardiopulmonary bypass during aortic valve replacement (AVR) for aortic valve stenosis (AVS)
      (Phase I) and optimize left ventricular reverse remodeling following AVR (Phase II).
      Preliminary evidence indicates that perioperative statin therapy reduce mortality and
      morbidity following cardiac surgery. Pleiotropic effects of statins may induce myocardial
      preconditioning and optimize myocardial and systemic responses to cardiopulmonary bypass
      during AVR. Furthermore statin therapy after AVR may contribute to an optimal left
      ventricular reverse remodeling.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>♦ Phase I: To study changes on inflammatory markers after aortic valve replacement. ♦ Phase II: To study changes in left ventricular mass at the end of the study (12 months).</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I: To study changes on mitochondrial function, reactive oxygen species, and perioperative systolic and diastolic functions. Phase II: To study changes on clinical status, systolic and diastolic functions during the one-year follow-up.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Ventricular Hypertrophy</condition>
  <arm_group>
    <arm_group_label>1: Atorvastatin 80 mg.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin 80 mg PO every day for one year. The treatment will start 4 weeks before aortic valve replacement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: No Atrovastatine</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 80 mg</intervention_name>
    <description>Atorvastatin 80 mg PO every day for one year. The treatment will start 4 weeks before aortic valve replacement.</description>
    <arm_group_label>1: Atorvastatin 80 mg.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; or = 70 years and &lt; 80 years

          -  Severe aortic valve stenosis

          -  Indication for aortic valve replacement by bioprothesis

          -  Ejection fraction &gt; or = 50%

          -  Without treatment with statin- No renal failure

          -  Informed consent signed

        Exclusion Criteria:

          -  Ischemic heart disaese

          -  Concomitant surgery to aortic valve replacement

          -  Emergency surgery- Known intolerance for statin

          -  Pregnant woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel KINDO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michel KINDO, MD</last_name>
    <phone>33.3.69.55.08.11</phone>
    <email>michel.kindo@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de Chirurgie Cardio-VasculaireHôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67 091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel KINDO, MD</last_name>
      <phone>33.3.69.55.08.11</phone>
      <email>michel.kindo@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2008</study_first_submitted>
  <study_first_submitted_qc>December 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2008</study_first_posted>
  <last_update_submitted>June 18, 2015</last_update_submitted>
  <last_update_submitted_qc>June 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Left ventricular hypertrophy</keyword>
  <keyword>Aortic valve stenosis</keyword>
  <keyword>Aortic valve replacement</keyword>
  <keyword>Cardiopulmonary bypass</keyword>
  <keyword>Statins</keyword>
  <keyword>Myocardial preconditioning</keyword>
  <keyword>Left ventricular reverse remodeling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

